Additionally, modifications in insulin signaling pathways through protein tyrosine phosphatase 1B (PTP1B), inhibition of inflammatory response, and oxidative stress lead to a decrease in MetS complications. The gene discussed is PTPN1; the disease is metabolic syndrome.